A bifunctional peptide–selenium nanocomposite for lysosomal degradation of PD-L1 and enhanced cancer immunotherapy
SA represents a novel intracellular PD-L1-targeted nanoplatform that promotes lysosome-mediated PD-L1 clearance, remodels the tumor immune milieu, and demonstrates superior antitumor performance compared to PD-L1 antibodies. This dual mechanism addresses key limitations of current ICB therapies and supports further clinical translation.
Authors
- Jun Feng (ORCID: https://orcid.org/0000-0002-5443-7158)
- Siqi Yan (ORCID: https://orcid.org/0000-0002-5905-3006)
- Weiming You
- Jin Yan (ORCID: https://orcid.org/0000-0001-6468-6003)
- Yang Wang (ORCID: https://orcid.org/0000-0001-6618-9748)
Institutions
- Second Affiliated Hospital of Xi'an Jiaotong University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1678911
- Primary Topic
- Selenium in Biological Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation